Biography
She holds a longstanding scientific interest in immunology, especially the role of B-cell signaling mechanisms in lupus and other autoimmune diseases.
In addition to taking care of patients in clinic and in the hospital, Dr. Chu enjoys teaching and mentoring fellows, residents, and medical students.
Professional Summary
Education & Certifications
- Residency: University of Chicago Hospitals Internal Medicine Residency (2005) IL
- Fellowship: Stanford University Rheumatology and Immunology Fellowship (2007) CA
- Board Certification: American Board of Internal Medicine, Rheumatology (2018)
- Medical Education: State University of New York - Buffalo (2002) NY
Publications
-
IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder
Hong, K., Chu, A., Ludviksson, B. R., BERG, E. L., & Ehrhardt, R. O. (1999). IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. JOURNAL OF IMMUNOLOGY, 162(12), 7480–7491. -
Tissue specificity of E- and P-selectin ligands in Th1-mediated chronic inflammation
Chu, A., Hong, K., BERG, E. L., & Ehrhardt, R. O. (1999). Tissue specificity of E- and P-selectin ligands in Th1-mediated chronic inflammation. JOURNAL OF IMMUNOLOGY, 163(9), 5086–5093. -
IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice
Thibault, D. L., Chu, A. D., Graham, K. L., Balboni, I., Lee, L. Y., Kohlmoos, C., … Utz, P. J. (2008). IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. JOURNAL OF CLINICAL INVESTIGATION, 118(4), 1417–26. -
Active and Latent Tuberculosis in Patients With Systemic Lupus Erythematosus Living in the United States
Chu, A. D., Polesky, A. H., Bhatia, G., & Bush, T. M. (2009). Active and Latent Tuberculosis in Patients With Systemic Lupus Erythematosus Living in the United States. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 15(5), 226–29. -
Natural Killer Cells From Children With Type 1 Diabetes Have Defects in NKG2D-Dependent Function and Signaling
Qin, H., Lee, I.-F., Panagiotopoulos, C., Wang, X., Chu, A. D., Utz, P. J., … Tan, R. (2011). Natural Killer Cells From Children With Type 1 Diabetes Have Defects in NKG2D-Dependent Function and Signaling. DIABETES, 60(3), 857–66. -
Measuring outcomes in systemic lupus erythematosus clinical trials
Strand, V., & Chu, A. D. (2011). Measuring outcomes in systemic lupus erythematosus clinical trials. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 11(4), 455–68. -
Generic Versus Disease-specific Measures of Health-related Quality of Life in Systemic Lupus Erythematosus
Strand, V., & Chu, A. D. (2011). Generic Versus Disease-specific Measures of Health-related Quality of Life in Systemic Lupus Erythematosus. JOURNAL OF RHEUMATOLOGY, 38(9), 1821–1823. -
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., … Hillmen, P. (2014). Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New England Journal of Medicine, 371(3), 213–23. -
Tetramers reveal IL-17-secreting CD4+ T cells that are specific for U1-70 in lupus and mixed connective tissue disease.
Kattah, N. H., Newell, E. W., Jarrell, J. A., Chu, A. D., Xie, J., Kattah, M. G., … Utz, P. J. (2015). Tetramers reveal IL-17-secreting CD4+ T cells that are specific for U1-70 in lupus and mixed connective tissue disease. Proceedings of the National Academy of Sciences of the United States of America, 112(10), 3044–49. -
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
Furie, R. A., LEON, G., Thomas, M., Petri, M. A., Chu, A. D., Hislop, C., … Scheinberg, M. A. (2015). A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. ANNALS OF THE RHEUMATIC DISEASES, 74(9), 1667–1675. -
Development of Th17-Associated Interstitial Kidney Inflammation in Lupus-Prone Mice Lacking the Gene Encoding STAT-1
Yiu, G., Rasmussen, T. K., Ajami, B., Haddon, D. J., Chu, A. D., Tangsombatvisit, S., … Utz, P. J. (2016). Development of Th17-Associated Interstitial Kidney Inflammation in Lupus-Prone Mice Lacking the Gene Encoding STAT-1. ARTHRITIS & RHEUMATOLOGY, 68(5), 1233–44. -
B-cell kinase inhibitors in rheumatoid arthritis
Chu, A. D., & Chang, B. Y. (2013). B-cell kinase inhibitors in rheumatoid arthritis. Open Access Arthritis, 1(2). -
Design of clinical trials in rheumatology
Strand, V., Sokolove, J., & Chu, A. D. (2013). Design of clinical trials in rheumatology. Oxford Textbook of Rheumatology. Oxford University Press. -
Assessing disease activity and outcome in systemic lupus erythematosus
Strand, V., & Chu, A. D. (2014). Assessing disease activity and outcome in systemic lupus erythematosus. Rheumatology. Elsevier. -
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., … Stilgenbauer, S. (2016). Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. LANCET ONCOLOGY, 17(10), 1409–18. -
Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
O'Brien, S., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K., … Byrd, J. C. (2018). Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. BLOOD, 131(17), 1910–19. -
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia A Pooled Analysis of 2 Clinical Trials
O'Brien, S. M., Jaglowski, S., Byrd, J. C., Bannerji, R., Blum, K. A., Fox, C. P., … Coutre, S. E. (2018). Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia A Pooled Analysis of 2 Clinical Trials. JAMA ONCOLOGY, 4(5), 712–16. -
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials
Jones, J., Mato, A., Coutre, S., Byrd, J. C., Furman, R. R., Hillmen, P., … O'Brien, S. M. (2018). Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials. BRITISH JOURNAL OF HAEMATOLOGY, 182(4), 504–12. -
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich, K., Teixeira, H. D., de Bruin-Weller, M., Bieber, T., Soong, W., Kabashima, K., … Silverberg, J. I. (2021). Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England), 397(10290), 2169–2181. -
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky, E., Teixeira, H. D., Simpson, E. L., Papp, K. A., Pangan, A. L., Blauvelt, A., … Irvine, A. D. (2021). Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet (London, England), 397(10290), 2151–2168. -
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
van der Heijde, D., Song, I.-H. H., Pangan, A. L., Deodhar, A., van den Bosch, F., Maksymowych, W. P., … Sieper, J. (2019). Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet (London, England), 394(10214), 2108–2117. -
Upadacitinib in Active Ankylosing Spondylitis: 1-Year Results From the Double-Blind, Placebo-Controlled SELECT-AXIS 1 Study and Open-Label Extension.
Deodhar, A., van der Heijde, D., Sieper, J., Van den Bosch, F., Maksymowych, W. P., Kim, T.-H. H., … Song, I.-H. H. (2021). Upadacitinib in Active Ankylosing Spondylitis: 1-Year Results From the Double-Blind, Placebo-Controlled SELECT-AXIS 1 Study and Open-Label Extension. Arthritis & Rheumatology (Hoboken, N.J.).
Practice Locations
Immunology and Rheumatology Clinic Palo Alto, CA
Palo Alto, CAImmunology and Rheumatology Clinic
900 Blake Wilbur Drive, 2nd Floor, Room W2081
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(4 reviews)
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records